VRTX · Market closed
$523.64
+0.56% today·exchange $523.64
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing transformative medicines for serious diseases, including cystic fibrosis, sickle cell disease, and acute pain, with key products such as TRIKAFTA and CASGEVY.
Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?
Simply Wall St. · 1d ago
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
Zacks · 1d ago
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
Zacks · 2d ago
Lilly’s latest China drug deal; Immunovant’s setback in lupus
BioPharma Dive · 2d ago
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool · 2d ago
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues
Simply Wall St. · 2d ago
Headlines from Yahoo Finance. Not investment advice.
